Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (otvara se novi prozor)

CRASH-3 Trial Collaborators

Izvor‎: Lancet 2019;394(10210):1713-23.

Indeks‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (otvara se novi prozor)

Alternatives to allogeneic platelet transfusion. (otvara se novi prozor)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Izvor‎: Br J Haematol 2016;175(3):381-92.

Indeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (otvara se novi prozor)

Tranexamic acid: less bleeding and less thrombosis? (otvara se novi prozor)

Godier A, Roberts I, Hunt BJ.

Izvor‎: Crit Care 2012;16(3):135.

Indeks‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (otvara se novi prozor)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (otvara se novi prozor)

Perel P, Ker K, Morales Uribe CH, Roberts I

Izvor‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Indeks‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (otvara se novi prozor)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (otvara se novi prozor)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Izvor‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Indeks‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (otvara se novi prozor)

Antifibrinolytic drugs for acute traumatic injury. (otvara se novi prozor)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Izvor‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Indeks‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (otvara se novi prozor)

Use of tranexamic acid to reduce bleeding in burns surgery. (otvara se novi prozor)

Tang YM, Chapman TW, Brooks P

Izvor‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Indeks‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (otvara se novi prozor)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (otvara se novi prozor)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Izvor‎: Burns. 2022;48(3):522-28.

Indeks‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (otvara se novi prozor)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (otvara se novi prozor)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Izvor‎: J Blood Med 2011;2:131-4.

Indeks‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (otvara se novi prozor)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (otvara se novi prozor)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Izvor‎: Transfusion 2009;49 Suppl 5:240S-7S.

Indeks‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (otvara se novi prozor)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (otvara se novi prozor)

Fries D

Izvor‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indeks‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (otvara se novi prozor)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (otvara se novi prozor)

Haan J, Scalea T

Izvor‎: Am Surg 2005;71(5):414-5.

Indeks‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (otvara se novi prozor)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (otvara se novi prozor)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Izvor‎: J Trauma 2010;69(3):489-500.

Indeks‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (otvara se novi prozor)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (otvara se novi prozor)

Hsia CC, Chin-Yee IH, McAlister VC.

Izvor‎: Ann Surg 2008;248(1):61-8.

Indeks‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (otvara se novi prozor)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (otvara se novi prozor)

Johansson PI, Eriksen K, Alsbjørn B

Izvor‎: J Trauma 2006;61(4):1016-8.

Indeks‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (otvara se novi prozor)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (otvara se novi prozor)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Izvor‎: ANZ J Surg 2013;83(3):155-60.

Indeks‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (otvara se novi prozor)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (otvara se novi prozor)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Izvor‎: Injury 2012;43(9):1409-14.

Indeks‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (otvara se novi prozor)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (otvara se novi prozor)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Izvor‎: Injury 2008;39(9):1054-61.

Indeks‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (otvara se novi prozor)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (otvara se novi prozor)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Izvor‎: Anesthesiology 2003;98(6):1513-5.

Indeks‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (otvara se novi prozor)

Alternatives to allogeneic platelet transfusion. (otvara se novi prozor)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Izvor‎: Br J Haematol 2016;175(3):381-92.

Indeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (otvara se novi prozor)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (otvara se novi prozor)

Fries D

Izvor‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indeks‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (otvara se novi prozor)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (otvara se novi prozor)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Izvor‎: Thromb Res 2014;134(2):360-8.

Indeks‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (otvara se novi prozor)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (otvara se novi prozor)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Izvor‎: Br J Haematol 2013;160(2):228-36.

Indeks‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (otvara se novi prozor)

Strategies to reduce the use of blood products: a European perspective. (otvara se novi prozor)

Theusinger OM, Felix C, Spahn DR.

Izvor‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Indeks‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (otvara se novi prozor)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (otvara se novi prozor)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Izvor‎: Anesthesiology 2008;109(6):1063-76.

Indeks‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (otvara se novi prozor)

Alternatives to allogeneic platelet transfusion. (otvara se novi prozor)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Izvor‎: Br J Haematol 2016;175(3):381-92.

Indeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (otvara se novi prozor)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (otvara se novi prozor)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Izvor‎: Blood Rev 2014;28(3):95-102.

Indeks‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (otvara se novi prozor)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (otvara se novi prozor)

Alperin JB

Izvor‎: JAMA 1987;258(14):1916-9.

Indeks‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (otvara se novi prozor)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (otvara se novi prozor)

Crowther MA, McDonald E, Johnston M, Cook D

Izvor‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Indeks‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (otvara se novi prozor)

The use of fibrin sealant in burn operations. (otvara se novi prozor)

Foster K

Izvor‎: Surgery 2007;142(4 Suppl):S50-4.

Indeks‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (otvara se novi prozor)

Use of fibrin sealant in thermal injury. (otvara se novi prozor)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Izvor‎: J Burn Care Rehabil 1997;18(5):429-34.

Indeks‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (otvara se novi prozor)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (otvara se novi prozor)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Izvor‎: Br J Anaesth 2012;109(3):376-81.

Indeks‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (otvara se novi prozor)

Transfusion in trauma: why and how should we change our current practice? (otvara se novi prozor)

Theusinger OM, Spahn DR, Ganter MT.

Izvor‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Indeks‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (otvara se novi prozor)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (otvara se novi prozor)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Izvor‎: Health Technol Assess 2015;19(58):1-228.

Indeks‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (otvara se novi prozor)